UCB Just Ditched a Biotech's IPO Plans With a $2 Billion Phone Call
UCB swooped in with $2 billion in cash to snag Candid Therapeutics, killing the company's planned IPO in the process. The deal spotlights big pharma's growing obsession with T-cell engagers for autoimmune disease and signals that 2026's M&A frenzy is just getting started.
Candid Therapeutics was weeks away from going public. The bags were packed, the paperwork was filed, and a reverse merger with Rallybio would have put the company on the Nasdaq with $505 million in fresh financing.
Then UCB showed up with $2 billion in cash and a simple pitch: skip the IPO circus.
The Belgian pharma giant announced it will acquire Candid Therapeutics in an all-cash deal worth up to $2.2 billion, including $2 billion upfront and another $200 million in milestone payments. Candid promptly terminated its Rallybio merger, paid a $50 million breakup fee, and never looked back.
It's the biotech equivalent of getting proposed to at someone else's wedding. Dramatic? Absolutely. But when the ring is worth $2 billion, you say yes.
What UCB Is Actually Buying
Candid isn't your typical acquisition target. The company doesn't have a blockbuster drug on the market, or even a late-stage clinical program. What it does have is a platform of T-cell engagers (TCEs): engineered antibodies designed to grab a T cell with one arm and a disease-causing cell with the other, essentially turning your immune system into a guided missile.
Think of it like a matchmaker at a party. T cells are the bouncers who can remove troublemakers, but they don't always know who to target. TCEs make the introduction: "Hey, bouncer, see that B cell over there? That's your guy."
Candid's lead asset, cizutamig, is a bispecific antibody that targets BCMA on plasma cells and CD3 on T cells. It's currently in Phase 1 trials across more than 10 autoimmune diseases, including rheumatoid arthritis, systemic sclerosis, and myasthenia gravis. Early data show favorable tolerability, low rates of cytokine release syndrome (the dangerous inflammatory overreaction that plagues many immune therapies), and signs of deep B-cell depletion in patients who hadn't responded to other treatments.
Behind cizutamig sits a second clinical program called CND261, a CD20×CD3 bispecific that completed a 93-patient oncology trial and is now being redirected toward autoimmune diseases. An additional trispecific candidate, targeting multiple B-cell markers simultaneously, is in preclinical development with a first-in-human trial expected in the first half of 2026.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Multiple shots on goal. Two already in the clinic. All built on the same underlying platform. That's what UCB is paying for.
The Bigger Pattern: UCB's Shopping Spree
This isn't an impulse buy. UCB has been methodically assembling the building blocks of a next-generation immunology powerhouse, and the Candid deal is the centerpiece of that strategy.
Rewind to March 2026: UCB signed a global license with Antengene for ATG-201, a CD19×CD3 bispecific antibody. That gave them one flavor of T-cell engager. Candid gives them more, including a BCMA-targeting program that fills a completely different biological niche.
Around the same time, UCB acquired Neurona Therapeutics for $1.15 billion, picking up a regenerative cell therapy for epilepsy. Different disease area, but same logic: buy advanced platforms, not just individual drugs.
To fund all of this, UCB has been selling off older assets. It offloaded its China neurology and allergy portfolio (think Keppra, Zyrtec) to CBC Group and Mubadala for $680 million. It also shed European rights to legacy brands like Atarax and Nootropil. Capital recycling at its finest: trade yesterday's revenue streams for tomorrow's growth engines.
The math works because UCB's core business is humming along. Management reaffirmed its 2026 revenue guidance (high single-digit to low double-digit growth) even after announcing the Candid deal, signaling that a $2 billion cash outlay won't dent near-term financial targets.
Why T-Cell Engagers Are Suddenly Worth Billions
A few years ago, TCEs were an oncology story. Amgen's Blincyto (a CD19×CD3 bispecific) proved the concept in blood cancers, and the rest of pharma started chasing similar programs. Today, the landscape has over 1,000 tracked TCE assets and a record number of Phase 2 trials running in 2025.
But the really interesting pivot is happening outside of cancer. Companies like Candid are taking the same T-cell engager technology and pointing it at autoimmune diseases. Instead of killing tumor cells, these drugs kill the rogue B cells and plasma cells that drive conditions like lupus, myasthenia gravis, and rheumatoid arthritis.
The idea is something researchers call an "immune reset": wipe out the malfunctioning immune cells, and the body rebuilds a healthier immune system from scratch. It's like reformatting a computer that's riddled with viruses, then letting it reinstall a clean operating system.
Big pharma is clearly buying the thesis. Genmab acquired Merus for roughly $8 billion in September 2025 to expand its bispecific antibody pipeline, centered on petosemtamab for head and neck cancer. BioNTech and Bristol Myers Squibb inked a co-development deal for BNT327 in June 2025.
The competitive dynamics are intensifying. Industry coverage explicitly notes that UCB is "joining Gilead" in the autoimmune TCE field, which means the race to own this modality is heating up fast.
The Rallybio Plot Twist
Perhaps the most telling detail in this whole saga is how the deal came together.
Candid had already struck its reverse merger agreement with Rallybio, a deal designed to give the company a public listing and half a billion in financing. It was the sensible, well-trodden path: go public, raise money, fund your trials.
But apparently, the Rallybio announcement acted like a bat signal for big pharma. CEO Ken Song reportedly fielded interest from multiple pharmaceutical companies after the reverse merger was announced. UCB emerged as the winner, offering a price that made the public markets route look like pocket change.
On May 3, 2026, Candid signed with UCB and terminated the Rallybio deal simultaneously. Rallybio gets its $50 million termination fee plus expense reimbursement, plans to withdraw its SEC registration statement, and goes home. Clean break.
The lesson for other private biotechs is clear: sometimes the best exit strategy is letting the market know you're available. Candid's reverse merger filing essentially functioned as a "for sale" sign, and UCB drove up with a moving truck.
What This Means for the Rest of 2026
The UCB-Candid deal is a signal flare, and it illuminates three things about where biotech M&A is headed.
First, platforms are commanding premiums over single assets. UCB didn't pay $2 billion for one drug. It paid for a modular TCE platform with multiple candidates, two clinical-stage programs, and the engineering capability to generate more. In a world where any single clinical trial can fail, owning the underlying technology is a form of insurance.
Second, European pharma is coming for American biotech. UCB, Chiesi, Angelini, Servier: a wave of European mid-cap and large-cap companies have been acquiring US biotechs throughout 2025 and 2026. They have the cash, the strategic urgency, and (in many cases) the pipeline gaps to justify aggressive deal-making.
Third, the autoimmune TCE space is about to get crowded. With UCB, Gilead, and others now staking claims, expect to see more deals, more clinical data, and more competition for the best programs. Companies sitting on differentiated TCE assets just became very popular at the pharma prom.
Analysts have called 2026 one of the most active biotech M&A years ever. The Candid acquisition suggests that pace isn't slowing down. If anything, the appetite is growing.
For UCB, the bet is straightforward but enormous. If cizutamig and its siblings deliver on the promise of immune reset in autoimmune disease, $2.2 billion will look like a bargain. If the clinical data disappoints, well, that's $2 billion you don't get back.
But that's the game in biotech. You place your bets before the cards are turned. UCB just pushed a very large stack of chips to the center of the table.
Clinical & Regulatory
4 min read
The Best Ulcerative Colitis Drug Nobody Wants to Buy Stock In
Abivax reported some of the best ulcerative colitis data ever seen, with 51% remission rates that blew away placebo. Then investors noticed the cancer cases in the safety tables, and the stock cratered 30-40% in a single day.
